Volume : 12, Issue : 01, January – 2025
Title:
A REVIEW ARTICLE ON: SUSTAINED RELEASE FORMULATIONS
Authors :
Rudra R. Chandel, Aditi Tikait, Dr. Swati P. Deshmukh
Abstract :
The objective of this study was to design and evaluate a sustained release formulation that maintains therapeutic drug levels over an extended period, enhancing patient compliance and treatment outcomes. A sustained release tablet formulation was developed using a combination of hydrophilic and hydrophobic polymers. The formulation was optimized based on in vitro release studies, which demonstrated a prolonged release profile, maintaining therapeutic drug levels over 24 hours.
Cite This Article:
Please cite this article in press Rudra R. Chandel et al., A Review Article On: Sustained Release Formulations.,Indo Am. J. P. Sci, 2025; 12 (01).
Number of Downloads : 10
References:
1. Chein YW. Novel Drug Delivery System. Revised and Expanded. 2nd ed. New York: Marcel Dekker; 2005.
2. Vamsy KA, Srinath KR, Chowdary PC. Formulation development and evaluation of divalproex sodium extended release tablet. Int J Res Pharm Biomed Sci 2011;2:809-32.
3. Jivraj I I, Martini LG, Thomson CM. An overview of the different excipients useful for the direct compression of tablets. Pharm Sci Technolo Today 2000;3(2):58-63.
4. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advance. New Delhi: Vallabh Prakashan; 2002. p. 155-95.
5. Longer MA, Robinson JR. Sustained release drug delivery system. In: Remington JP, editor. The Science and Practice of Pharmacy. 18th ed. Philadelphia: The Philadelphia College of Pharmacy and Science; 1990. p. 1677-9.
6. Wani MS, Controlled release system-A. Rev 2008;6(1): www. pharmainfo.net/review. Available from: http://www.pharmainfo.net/ reviews/controlled-released-system-review.
7. Bechgaard H, Nielson GH. Controlled release multiple units and single unit dosage. Drug Dev Ind Pharm 1978;4(1):53-67.
8. Bhowmik D, Kumar KP, Dutta A, Paswan S. Trends in scope and opportunities of control release oral drug delivery systems. Crit Rev Pharm Sci 2012;1:20-33.
9. Patel H, Panchal DR, Patel U, Brahmbhatt T. Matrix type drug delivery system: A review. J Pharm Sci Biosci Res 2011;1(3):143-51.
10. Dixit N, Maurya SD, Bhanu PS. Sustained release drug delivery system. Indian J Res Pharm Biotechnol 2013;1:305-10.
11. Kola R, Kumar BP. A detailed description of synthetic and natural polymers which are used in the formulation of sustained release drug delivery system: A review. J Chem Pharm Sci 2013;6:161-9.
12. Ratnaparkhi MP, Gupta JP. Sustained release oral drug delivery system – An overview. Int J Pharm Res Rev 2013;2:11-21.
13. Pundir S, Badola A, Sharma D. Sustained release matrix technology and recent advance in matrix drug delivery system: A review. Int J Drug Res Tech 2013;3:12-20
14. Marroum PJ. Bioavailability/Bioequivalence for Oral Controlled Release Products, Controlled Release Drug Delivery Systems: Scientific and Regulatory Issues, Fifth International Symposium on Drug Development, East Brunswick, NJ: May-15-17, 1997.
15. Kumar KP, Bhowmik D, Srivastava S. Sustained release drug delivery system potential. Pharm Inov 2012;1:48-60.
16. Lee TW, Robinson JR. In: Gennaro AR, editor. Remington: The Science and Practice of Pharmacy. 20th ed. Baltimore: Lippincott Williams and Wilkins; 2000. p. 903-29.
17. Allen, L. V. & Ansel, H. C. in Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems 10th edn (Lippincott Williams & Wilkins, 2017).
18. Burgess, D. J. & Wright, J. C. in Long Acting Injections and Implants (eds Wright, J. C. & Burgess, D. J.) 1–9 (Springer, 2012).
19. Wright, J. C. & Hoffman, A. S. in Long Acting Injections and Implants (eds Wright, J. C. & Burgess, D. J.) 11–24 (Springer, 2012).
20. Thakur, R. R., McMillan, H. L. & Jones, D. S. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants. J. Control. Release 176, 8–23 (2014).
21. Packhaeuser, C. B., Schnieders, J., Oster, C. G. & Kissel, T. In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. 58, 445–455 (2004).
22. Parent, M. et al. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release. J. Control. Release 172, 292–304 (2013).
23. Perez-Marreno, R. et al. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin. Ther. 24, 1902–1914 (2002).
24. Stewart, S. A., Dominguez-Robles, J., Donnelly, R. F. & Larraneta, E. Implantable polymeric drug delivery devices: classification, manufacture, materials, and clinical applications. Polymers 10, 1379 (2018).
25. Silva, G. R. D., Fialho, S. L., Siqueira, R. C., Jorge, R. & Cunha Júnior, A. D. S. Implants as drug delivery devices for the treatment of eye diseases. Braz. J. Pharm. Sci. 46, 585–595 (2010).
26. Odom, E. B., Eisenberg, D. L. & Fox, I. K. Difficult removal of subdermal contraceptive implants: a multidisciplinary approach involving a peripheral nerve expert. Contraception 96, 89–95 (2017).
27. Bourges, J. L. et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv. Drug Deliv. Rev. 58, 1182–1202 (2006).
28. Yasukawa, T. et al. Drug delivery systems for vitreoretinal diseases. Prog. Retin. Eye Res. 23, 253–281 (2004).
29. Al-Jawadi, S., Capasso, P. & Sharma, M. The road to market implantable drug delivery systems: a review on US FDA’s regulatory framework and quality control requirements. Pharm. Dev. Technol. 23, 953–963 (2018).
30. Li, J. & Mooney, D. J. Designing hydrogels for controlled drug delivery. Nat. Rev. Mater. 1, 1–17 (2016).
31. Lee, W. Y., Asadujjaman, M. & Jee, J.-P. Long acting injectable formulations: the state of the arts and challenges of poly (lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal. J. Pharm. Investig. 49, 459–476 (2019).